Nexelis services

For R&D in Immunogenicity, Immuno-Oncology, and Cell and Gene Therapy. We have exceptional in vitro bioassay development services and support for early evaluation and screening of candidate therapeutics. Our highly experienced team will facilitate in silico immunogenicity assessment with epitope prediction to in vitro immunogenicity and immuno-functionality assays.

Custom In Vivo Models and Testing Solutions. Selecting the appropriate in vivo model for your assays is critical for the success of your preclinical research program. At Nexelis, a Q² Solutions Company, we designed and developed disease specific in vivo models alongside bespoke personalized model development services. Our wealth of experience and capabilities allows us to help answer our clients’ research questions and aid with the most appropriate study design. We provide non-regulated, preclinical development solutions that include performing experiments, analysis, reporting, and technical writing.

Molecular Biology and Protein Expression, Purification, and Characterization. When you partner with the Nexelis, a Q² Solutions Company, we will work closely with you from concept through delivery. Our services are fully flexible according to your needs and can be engaged as stand-alone tests or as a comprehensive package. You receive proteins tailored to your specifications in scale, purity, activity, and other analytical characteristics — on a timeline that meets your needs.

Including Pharmacokinetics and Immunogenicity. Designed to be an extension of your laboratory, Nexelis, a Q² Solutions Company, supports bioanalysis in all phases with agile assay development to validation mindset. Whether we design a custom bioanalytical assay or support a client’s technology transfer, our method development process results in an optimized assay compliant with global standards. Our organization commits to continued investment and development in bioanalytical methods. Clients in the pharmaceutical, biotech, and animal health industries rely on us for the complete range of comprehensive bioanalytical services for all modalities.

Testing Services to Support Your Preclinical and Phase I-IV Drug Programs. Nexelis, a Q² Solutions Company, provides biomarker assay services in inflammation and immunology, oncology, organ injury (renal), nutritional health, cardiovascular, metabolic (NASH/NAFLD) and infectious diseases. Our scientists approach your projects with flexible and creative solutions, developing fit-for-purpose to validated assays that support your protocol.

Custom Assay Development to Advance Molecules. You need reliable approaches to support what’s next in your development programs whether they are complex small molecules, advanced biologics, or vaccines. At Nexelis, a Q² Solutions Company, we break down barriers to translational research through innovation and collaboration, helping you deliver better treatments to more patients, sooner. With an extensive track record developing, qualifying, validating, and transferring tests, our dedicated scientists support programs, from early development to clinical Phase I-IV.

From Fit-for-Purpose Development to Qualified and Validated Clinical Assays. Nexelis, a Q² Solutions Company, is a leading partner in assay development and technology transfer, with scientific discipline, critical thinking, and agility. Fit-for-purpose assay development on a wide variety of platforms support your small molecule, large molecule, or vaccine program through all phases of development. We have vast experience with assay transfer, developing 250+ successful assays and transferring them to sponsors around the globe. Our team has a wealth of biopharmaceutical and CRO industry experience developing and troubleshooting complex assays that meet regulatory requirements. With a track record supporting more than 350+ IND and regulatory filings, you can count on us for strategic pre-IND, IND, and late-stage collaboration with your regulatory agency.

Accelerating Drug Development Process at Scale: Nexelis, a Q² Solutions Company, utilizes automated systems for high throughput through our investment in robotics to support our scientists, who generate over 1.5 million results annually. Our immense capacity helps accelerate the drug discovery and clinical trial process. Controlling for variability when performing manual processes at the order of magnitude required for large sample volume throughput is virtually impossible. However, our investment in automation helps our team to deliver consistently with accuracy, reproducibility, and precision to meet client’s expectations and timelines. Our automated, validated data reporting systems also ensure objectivity when generating results. With state-of-the-art equipment at our facilities globally, our team produces data for large scale projects with increased output for consistent and timely delivery of results.

Robotics: Nexelis has invested in state-of-the-art automation platforms that allow in-house High Throughput Screening (HTS). With robotics to support our specialty lab testing platforms, our laboratories are integrated with industry leading turnkey solutions ranging from assay set up and execution to sample storage, including automated labeling. Robotic workstations have several advantages over manual processes as robots can work continuously to increase the throughput, perform consistently, and ensure accuracy and precision. With our ability to quickly scale-up operations, our teams are well-equipped to meet market demands without compromising the flexibility and agility we are known for.

Our automatic liquid handlers can detect a broad range of immune markers in the serum, plasma, or cell culture supernatants. Automation has increased our testing capacity, as compared to manual experiments, particularly for pipetting operations. We can perform sample preparation, dilution, and plating and pressure-monitored pipetting. Our robotic liquid handling workstations can track barcodes and provide fully traceable results.